The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2, open-label, first-in-human study of the anti-GPC3 T-cell engager SAR444200 in patients with advanced solid tumors: Updated efficacy and biomarker analysis.
 
Ecaterina Dumbrava
Consulting or Advisory Role - Bolt Biotherapeutics; Fate Therapeutics; Mersana; PMV Pharma; Summit Therapeutics
Speakers' Bureau - PMV Pharma
Research Funding - A2A Pharmaceuticals (Inst); Aileron Therapeutics (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Compugen (Inst); Dragonfly Therapeutics (Inst); Fate Therapeutics (Inst); Genentech (Inst); Immunocore (Inst); Immunomedics/Gilead (Inst); Mereo BioPharma 5 (Inst); Mersana (Inst); ModeX Therapeutics (Inst); Pfizer (Inst); PMV Pharma (Inst); Poseida (Inst); Rain Therapeutics (Inst); Sanofi (Inst); Sotio (Inst); Triumvira Immunologics, Inc (Inst); Volastra Therapeutics (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Rain Oncology; Triumvira Immunologics, Inc
 
Anthony El-Khoueiry
Honoraria - Agenus; AstraZeneca/MedImmune; Bristol Myers Squibb Foundation; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; QED Therapeutics; Qurient; Roche; Senti Biosciences; SERVIER; Tallac Therapeutics, Inc.
Consulting or Advisory Role - Agenus; AstraZeneca/MedImmune; Bayer; Bristol Myers Squibb Foundation; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; QED Therapeutics; Qurient; Roche; Senti Biosciences; SERVIER; Tallac Therapeutics, Inc.
Research Funding - Astex Pharmaceuticals; AstraZeneca/UK; Fulgent Genetics
 
Jens Samol
Consulting or Advisory Role - AstraZeneca/UK; BeiGene; Bristol Myers Squibb Foundation; Eisai; Ipsen; Merck Sharp & Dohme; Roche; Taiho Pharmaceutical
Research Funding - AstraZeneca/UK
Travel, Accommodations, Expenses - AstraZeneca/UK; Merck Sharp & Dohme
 
Khaldoun Almhanna
No Relationships to Disclose
 
Jung Yong Hong
No Relationships to Disclose
 
Maxime Chenard-Poirier
Honoraria - Bristol Myers Squibb Foundation; Eisai; Incyte; Merck
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Boon Cher Goh
No Relationships to Disclose
 
Asma Kefsi
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Raymond Perez
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Robin Meng
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
Travel, Accommodations, Expenses - Sanofi
 
Serena Masciari
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Giovanni Abbadessa
Employment - Alexion Pharmaceuticals (I); Sanofi
Leadership - ModeX Therapeutics
Stock and Other Ownership Interests - Alexion Pharmaceuticals (I); OPKO Health; Sanofi
Patents, Royalties, Other Intellectual Property - patents on Alexion experimental drugs (I); patents on Sanofi experimental anti-cancer drugs
 
Benoit Pasquier
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Helene Guillemin-Paveau
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Lucie Lepine
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Yiding Zhang
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Darren Lim
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)